Antibiotics for Vancomycin-Resistant Infections

First-Line Treatment Options by Infection Type

The Infectious Diseases Society of America recommends Linezolid 600 mg IV q12h as first-line therapy for VRE bacteremia, with high-dose daptomycin (8-12 mg/kg IV daily) as an effective alternative 1, 2
For complicated intra-abdominal infections, Linezolid 600 mg IV q12h is the primary recommendation, with Tigecycline (100 mg IV loading dose, then 50 mg IV q12h) specifically recommended for intra-abdominal infections due to VRE 1, 2
The American College of Clinical Pharmacy suggests that for VRE pneumonia, Linezolid 600 mg IV q12h is the recommended treatment, with a treatment duration of at least 7 days 2

Linezolid works by inhibiting bacterial protein synthesis at the pre-translational initiation complex formation, and has bacteriostatic activity against vancomycin-resistant E. faecium and E. faecalis 1
Daptomycin exhibits bactericidal activity, making it particularly valuable for bloodstream infections 1

For VRE bloodstream infections with high daptomycin MIC, combination with beta-lactams may be beneficial, according to the European Society of Clinical Microbiology and Infectious Diseases 2
Linezolid shows synergistic activity with beta-lactam antibiotics against VRE infections, as reported by the Infectious Diseases Society of America 3

Newer agents with activity against VRE include Eravacycline for intra-abdominal infections, as recommended by the Society for Healthcare Epidemiology of America 1
Ceftaroline has in vitro activity against gram-positive organisms but poor activity against enterococci and should not be used empirically for VRE infections, according to the American Society for Microbiology 4

The Centers for Disease Control and Prevention recommend distinguishing between colonization and true infection before initiating anti-VRE therapy, and avoiding empiric vancomycin use in neutropenic patients with persistent fever if culture results remain negative after 72-96 hours 4, 5, 6
For VRE endocarditis, cardiac surgery combined with antimicrobial therapy should be considered for optimal outcomes, as suggested by the American Heart Association 2